Investigation of upper gastrointestinal bleeding after implantation of drug-eluting stents; Prospective cohort study

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 9, 2010, Pages 1097-1100

  Toyokawa, Tatsuya ^a   Inaba, Tomoki ^b   Ishikawa, Shigenao ^b   Nakatsu, Morihito ^c   Ando, Masaharu ^c   Tomoda, Jun ^a  

^a NATIONAL HOSPITAL ORGANIZATION FUKUYAMA MEDICAL CENTER   (Japan)

^b Kagawa Prefectural Central Hospital   (Japan)

^c Mitoyo General Hospital   (Japan)

Author keywords

Anti thrombotic agents; Drug eluting stents; Low dose aspirin; Prospective cohort study; Upper gastrointestinal bleeding

Indexed keywords

ACETYLSALICYLIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; TICLOPIDINE; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FEMALE; HEMATEMESIS; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STENT THROMBOSIS; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DRUG-ELUTING STENTS; FEMALE; FIBRINOLYTIC AGENTS; GASTROINTESTINAL HEMORRHAGE; HEMATEMESIS; HUMANS; INCIDENCE; MALE; MELENA; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77955534962     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521003797197     Document Type: Article

References (16)

1. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115: 813-818.
2. Derry S, Loke YK. Risk of gastrointestinal hemorrhage with long term use of aspirin:meta-analysis. BMJ 2000;321: 1183-1187.
3. Sakamoto C, Sugano K, Ota S, Sasaki N, Takahashi S, Yoshida Y, et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal antiinflammatory drugs in Japan. Eur J Clin Pharmacol 2006;62: 765-772.
4. Holvoet J, Terriere L, Van HW, Verbist L, Fierens E, Hautekeete ML. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a casecontrol study. Gut 1991;32:730-734.
5. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, OShaughnessy C, et al. Sirolimus-Eluting stent versus Standard Stents in Patients with Stenosis in a Native Coronary Artery. N Eng J Med 2003;349:1315-1323.
6. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stancovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
7. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-168.
8. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors followingacutecoronarysyndrome.JAMA2009;301:937-944.
9. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-718.
10. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006;119:624-638.
11. Ng W, Wong WM, Chen WH, Tse HF, Lee PY, Lai KC, et al. Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events patients with coronary artery disease. World J Gastroenterol 2006;12:2923-2927.
12. Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002;16:1945-1953.
13. Graham DY, Agrawal NM, Roth SH. Prevention of NSAIDinduced gastric ulcer with misoprostol: multicentre, doubleblind, placebo-controlled trial. Lancet 1988;332:1277-1280.
14. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs.NEng J Med 1996;334:1435-1439.
15. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Eng J Med 1998;338:727-734.
16. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and esophagitis in patients taking low-dose aspirin(FAMOUS): a phase III, randomized, double-blind, placebo-controlled trial. Lancet 2009;374: 119-125.